Texas Children’s Cancer Center receives $10 million gift to open the Fayez Sarofim Lymphoma Center, the world’s first pediatric lymphoma research center
HOUSTON – (June 26, 2012) – Texas Children’s Cancer Center announced today the opening of the Fayez Sarofim Lymphoma Center, the first and only center in the world dedicated specifically to the research, care and treatment of children with lymphoma. This innovative research center was made possible by a generous gift of $10 million to Texas Children’s Hospital.
Cancer remains the leading cause of non-accidental death in children and lymphomas are the third most common malignancy in childhood. Modern therapies to treat children with lymphomas primarily involve chemotherapy which is occasionally supplemented with radiation treatment. Although the outlook for children with lymphoma has generally improved in recent years, substantial challenges still exist. First, not all lymphoma patients respond to initial treatment and a significant portion of those patients who do respond initially will eventually relapse – usually the result of the development of drug resistance. Additionally, current treatments can be associated with both short-term and long-term adverse effects that may negatively impact a lymphoma survivor’s quality of life.
Texas Children’s Hospital is helping to address these issues in the newly formed Fayez Sarofim Lymphoma Center at Texas Children’s Cancer Center which will conduct breakthrough laboratory research on the biology of lymphomas, use the information gained from laboratory and basic research to develop new diagnostic approaches and identify novel therapeutic targets and new approaches to therapy.
“Our researchers have already developed effective cell-based therapies that have demonstrated extremely exciting clinical results and we are also evaluating new chemotherapeutic agents with significant clinical promise. The formation of this new research center will allow the physician scientists and researchers at Texas Children’s Cancer Center to expand on this progress in exponential ways,” said. Dr. Catherine Bollard, director of the Fayez Sarofim Lymphoma Center.
This new center will become the leading site for the development of new diagnostic and therapeutic approaches for the treatment of childhood lymphoma and the focal point for childhood lymphoma research. The advances made at the center will not only impact patients at Texas Children’s Cancer Center, but children throughout the country and around the world who will be treated on therapies developed at this new research center. Advances made at the center will be shared with pediatric oncologists around the world.
“The breakthrough discoveries that take place in the laboratories of the Fayez Sarofim Lymphoma Center will represent the future of lymphoma treatment and the best hope for children with this disease,” said Dr. David Poplack, director of Texas Children’s Cancer Center and professor of pediatric oncology at Baylor College of Medicine. “This generous gift ensures our physicians and researchers are able to continue developing the most advanced therapies in our search for a cure for pediatric lymphoma.”
In recent years, Texas Children’s Cancer Center has amassed a significant group of clinical and laboratory researchers who possess unique skills in the field of lymphoma research. The Cancer Center has a unique translational research infrastructure already in place which comprehensively integrates both laboratory and clinical research efforts and the research advances that emanate from these laboratories are rapidly translated into clinical studies. In fact, Texas Children’s Cancer Center conducts more new agent studies for childhood cancer than any center in the world.
Dr. Kenneth McClain, clinical director of the new Fayez Sarofim Lymphoma Center noted that “this extraordinary gift will help expand the number of innovative therapies that will be available to treat our young patients. Our ultimate goal is to find a cure for all children with lymphoma.”
About Texas Children's Cancer Center
As an international leader in pediatric cancer research and treatment, Texas Children's Cancer Center is dedicated to providing novel therapies and family-centered care to children from infancy through young adulthood with cancer and blood disorders – from the most common to rare. The Texas Children’s Cancer Center is a joint program of Texas Children’s Hospital and Baylor College of Medicine and is the pediatric program of BCM’s NCI-designated Dan L. Duncan Cancer Center. U.S.News & World Report ranked the Center #1 outside the northeast United States, as well as #1 in Texas. Texas Children’s Cancer Center treats more childhood cancer patients than any other program in the U.S., with patients coming from 35 states and 26 countries around the world.
- May 14, 2013
- 'Off-the-shelf' virus-specific T-cells fight viral infections in stem cell transplant patients
Viral infections present deadly threats to patients who have received donor blood, marrow and cord stem cells transplants and are immune deficient while their transplants begin to work.
- April 9, 2013
- BCM major part of new pediatric cancer Dream Team initiative
Baylor College of Medicine is part of a Dream Team of childhood cancer researchers that will focus on melding the fields of genomics and immunotherapy to advance treatment for pediatric cancer.
- March 28, 2013
- Wipe Out Kids’ Cancer donates $75,000 to Texas Children’s Cancer Center
The grant will be used to fund a research project on neuroblastoma, an aggressive pediatric cancer that strikes approximately 650 children a year in the U.S., usually before age 5.
- March 1, 2013
- Fundraiser supports pediatric cancer in South Texas
Actor Diego Boneta, top right, helped raised $90,000 for the Vannie Cook Children’s Cancer Clinic in South Texas at the 2013 Radiothon.
- February 27, 2013
- Hematology-oncology faculty members receive renewed NIH funding to enhance T cell therapy for cancer
Hematology-oncology faculty members from the Center for Cell and Gene Therapy (CAGT) have received a $11.3 million renewal grant from the National Institutes of Health to advance the development of more effective and less toxic targeted T cell therapies for children and adults with cancer.
- February 1, 2013
- Grant funds developmental therapeutics program
A five-year, $1.75 million grant from Alex’s Lemonade Stand Foundation was awarded to Texas Children’s Cancer Center to establish the Developmental Therapeutics Center of Excellence.
- January 4, 2013
- Houston Radio Host Kevin Kline Completes his 62,000 Step Stair Run
Kevin Kline, Houston morning radio host on The New 93Q, ran 62,000 Stairs at Constellation Field, home of the Sugar Land Skeeters Baseball team in Sugarland, TX.
- December 12, 2012
- Vegetable compound could become ingredient to treating leukemia
A concentrated form of a compound called sulforaphane found in broccoli and other cruciferous vegetables has been shown to reduce the number of acute lymphoblastic leukemia cells in the lab setting, said researchers at Baylor College of Medicine. The findings appear in the current edition of PLOS ONE.
- December 11, 2012
- Montblanc and Texas Children’s Cancer Center encourage families to give a gift that counts this holiday season
Montblanc and Texas Children’s Cancer Center have launched a new initiative allowing people across the United States to show their support for children and adolescents fighting cancer by providing an opportunity to purchase a specially designed bracelet to be given to the parent of a pediatric cancer patient this holiday season.
- December 6, 2012
- Q&A: Sharon Plon on Baylor College of Medicine's First Year of Clinical Exome Sequencing
As a member of Baylor College of Medicine's Whole Genome Laboratory management committee, Sharon Plon has been a leader in establishing Baylor's clinical exome sequencing diagnostic test, which was launched last November.
This is part one of a two-part interview. Part two will appear in next week's issue.